Alfred Mann Foundation Creates New Medical Device Firm

The Alfred Mann Foundation (AMF) has created Medallion Therapeutics, Inc., a life sciences company that will provide targeted delivery solutions for pharmaceuticals and biologic therapies. Medallion Therapeutics has recruited industry veteran executives Donald L. Deyo as CEO and Eric S. Harris as chief commercial officer.

The Medallion Therapeutics product line is based on novel implantable drug delivery infusion pump developed by AMF scientists and engineers to provide superior safety, connectivity and large molecule infusion capabilities. These capabilities address both the requirements of currently approved clinical indications, as well as enable future expansion into new indications in areas such as diabetes and neurodegenerative disease. Medallion Therapeutics is the result of more than 10 years of research and development to create the Medallion implantable drug delivery system. The company currently is conducting a pivotal clinical evaluation in the United States to support an upcoming submission for pre-market approval (PMA), as well as pursuing CE Mark certification to support distribution in Europe.

Founded in 1985 by healthcare entrepreneur Alfred E. Mann, AMF has developed and commercialized several medical devices. The formation of the new venture reflects the strategy of AMF to develop solutions to major unmet medical needs and create companies to commercialize the innovation once mature. “The Medallion Therapeutics pump holds the promise of providing patients and physicians with a superior method of infusion therapy than current market alternatives,” Alfred Mann Foundation CEO David Hankin said. “Don Deyo, Eric Harris and the group of AMF professionals joining Medallion Therapeutics constitute a world class team that will bring this innovative solution to patients around the globe.”

Deyo noted, “The AMF engineers have created a tremendous platform that addresses major needs associated with currently-marketed implantable delivery devices, as well as opens the door to targeted delivery of large molecules associated with novel biologic therapies for neurodegenerative diseases. Our U.S. clinical study is moving rapidly toward achieving the enrollment required for PMA submission.”

Harris said a “tremendous need” exists in the market for the infusion, safety and connectivity capabilities of the Medallion system in all established indications. “I look forward to building upon the experience of our leadership team in this market to earn the confidence with clinicians around the world in for our innovative solutions for their patients,” he added.

Medallion Therapeutics is a medical technology and life sciences company located in Minneapolis-St. Paul, Minn. The late-stage start-up company is pursuing global commercial approval of an implantable infusion line that expands the potential application to additional clinical indications.

The Alfred Mann Foundation for Scientific Research has developed a myriad of medical devices, including a cochlear implant that enables deaf people to hear, several diabetes products, and various devices in the neural space for the eradication of pain and recovery of function. AMF is located in Santa Clarita, Calif.